Welldoc seeks FDA nod for AI-based glucose prediction in non-insulin type 2 diabetes
Welldoc’s CGM-based glucose prediction tool for non-insulin users is now under FDA review. Find out what it could change in diabetes care.
Welldoc’s CGM-based glucose prediction tool for non-insulin users is now under FDA review. Find out what it could change in diabetes care.